Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Systemic Lupus Erythematosus (SLE) · Lupus Nephritis (LN)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing GoBroad Hospital, Beijing, Beijing Municipality, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus · Lupus Nephritis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orange, United States · Sacramento, United States

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells

Lupus Nephritis · Lupus Erythematosus

Abroad (travel likely)RecruitingPHASE2

Valladolid, Spain

Biomarker Development for Autoimmune Disorders Involving the Kidneys

Lupus Nephritis · Systemic Lupus Erythematosus

Abroad (travel likely)Recruiting

Oslo, Norway

Lupus Landmark Study: A Prospective Registry and Biorepository

Systemic Lupus Erythematosus (SLE) · Lupus Nephritis · Neuropsychiatric Systemic Lupus Erythematosus

Abroad (travel likely)Recruiting

Birmingham, United States · Tucson, United States